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Abstract: Pre-eclampsia is a significant, multifactorial, multiorgan disease affecting 5%–8% 
of all pregnancies in the US where it is the third leading cause of maternal mortality. Despite 
improvements in the diagnosis and management of pre-eclampsia, severe complications can 
occur in both the mother and the fetus, and there is no effective method of prevention. Early 
detection and identification of pregnant women most at risk of developing the disease have proven 
challenging, but recent efforts combining biochemical and biophysical markers are   promising. 
Efforts at prevention of pre-eclampsia with aspirin and calcium have had limited   success, 
but research on modifiable risk factors, such as obesity surgery, are encouraging. Obstetric 
  management of severe pre-eclampsia focuses on medical management of blood pressure and 
prevention of seizures using magnesium sulfate, but the ultimate cure remains delivery of the 
fetus and placenta. Timing of delivery depends on several factors, including gestational age, fetal 
lung maturity, and most importantly, disease severity. Anesthetic management includes regional 
anesthesia with careful evaluation of the patient’s airway, volume status, and coagulation status 
to reduce morbidity and mortality. The potential complications of general anesthesia, including 
intracranial hemorrhage, in these patients make regional anesthesia the preferred choice in many 
cases. Nevertheless, it is important to be aware of the contraindications to neuraxial anesthesia 
and to prepare always for the possibility of encountering a difficult airway.
Keywords: pre-eclampsia, diagnosis, risk factors, complications, management, anesthesia, 
prevention
Introduction
Pre-eclampsia is a diverse, multiorgan group of related disease processes that occurs in 
up to 5%–8% of pregnancies after 20 weeks’ gestation. The presentation is highly vari-
able, but generally includes the combination of maternal hypertension and   proteinuria. 
The etiology of the disease is likely multifactorial, and its initial presentation may be 
mild or severe, including eclamptic grand mal seizures.
Globally, pre-eclampsia and eclampsia account for 10%–15% of maternal 
deaths. The majority of deaths in developing countries result from eclampsia, 
while in developed countries, complications of pre-eclampsia are more often the 
cause.1 In the US, pre-eclampsia is the third leading cause of maternal mortality, 
accounting for 54 of 540 maternal deaths in 2004, behind only embolism and hem-
orrhage.2 It can also lead to significant fetal morbidity and mortality, including an 
increased incidence of placental abruption, fetal growth restriction, and preterm 
delivery. Given its frequent occurrence and potential severity, early diagnosis and 
appropriate management are essential.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Diagnosis
The term pre-eclampsia refers to a group of related   hypertensive 
disorders of pregnancy. Mild pre-eclampsia has historically been 
characterized by hypertension with two readings of systolic blood 
pressure (BP) $ 140 mmHg and/or diastolic BP $ 90 mmHg, 
separated by a 4- to 6-hour period, and proteinuria with a urine 
dipstick of $ 1+ or $ 300 mg per 24 hours, after 20 weeks’ 
gestation in a previously normotensive parturient (Table 1).3–5 
Signs of the disease should remit by 6–12 weeks postpartum. 
The diagnostic criteria of the disease have been revised over 
the past decade, such that edema is no longer required and even 
proteinuria without a worsening creatinine level may be less 
of a concern than previously suspected.5 The progression of 
the disease state is highly variable. It may worsen from a mild 
to severe state, or to eclampsia, without warning, or it may be 
severe at the time of diagnosis.
Severe pre-eclampsia has been characterized by 
one or more of the following criteria: sustained systolic 
BP $ 160 mmHg or diastolic BP $ 110 mmHg while on 
bed rest, nephrotic-range proteinuria, sudden oliguria, central 
nervous system disturbances, pulmonary edema or cyanosis, 
epigastric or right upper quadrant pain, liver dysfunction, 
thrombocytopenia, and fetal growth restriction.3–5 Thus, 
severe pre-eclampsia may be diagnosed even with mildly 
elevated BP if there is other evidence of significant end-
organ disease.
The distinction between early and late pre-eclampsia is a 
more modern concept and is becoming widely accepted as a 
better indicator of disease significance than the classic “mild” 
versus “severe” terminology. There is evidence that more 
severe disease is associated with early onset, prior to 34 weeks’ 
gestation, supporting the concept that the etiology of this dis-
ease may be different from that of later onset pre-eclampsia.3 
Early onset disease appears to be mediated by the placenta, 
and is associated with abnormal uterine artery D  oppler flow, 
fetal growth restriction, and adverse maternal and fetal out-
comes.5,6 Later onset of the disease (after 34 weeks’ gestation) 
has been linked to maternal “  constitutional” factors, such as 
body mass index (BMI), and may be associated with more 
favorable outcomes.6 Because the etiology of the disease 
appears to vary according to the time of presentation, so too 
do the maternal hemodynamics. Valensise et al studied 1345 
nulliparous patients identified as normotensive with bilateral 
uterine notching at 20–22 weeks’ gestation. When evaluated 
at 24 weeks’ gestation, patients who went on to be diagnosed 
with early disease had higher total vascular resistance and 
lower cardiac output, while late onset patients had higher 
prepregnancy BMI, higher cardiac output, and lower total 
vascular resistance when compared with the early onset and 
control patients, supporting the concept of differing disease 
etiologies.6
In a recent review and opinion article on proteinuria in 
pregnancy, Lindheimer and Kanter point out that there are 
no strong data to support the 300 mg/24 hour cutoff com-
monly used to diagnose pre-eclampsia, and that there is 
little consensus of opinion as to what degree of proteinuria 
is “severe”.7 Protein handling is altered in pregnancy and 
many factors can affect the amount of proteinuria apart from 
renal pathology, including steroids given for lung maturity. 
If disease is present, even small changes in tubular levels 
of proteinuria can cause significantly increased proteinuria 
because tubular reabsorption is presumably already maxi-
mized. They conclude that management decisions should 
probably not be based solely on the degree of proteinuria 
beyond initial diagnosis,7 but rather on other more reliable 
indicators of disease severity, such as BP, liver dysfunction, 
or deteriorating neurologic status.
The urine protein/creatinine ratio (UPCR) has been 
used to provide a less time-consuming test of proteinuria 
when a   diagnosis of pre-eclampsia is being considered. 
Table 1 Diagnostic criteria for pre-eclampsia4,5,7
Onset of symptoms after 20 weeks’ gestation with remission by 
6–12 weeks postpartum*
Mild pre-eclampsia:
 •    Hypertension (SBP $ 140 mmHg or DBP $ 90 mmHg), may be 
superimposed on chronic hypertension
 •    Proteinuria (proteinuria $ 300 mg/24 hours, or significant increase 
from baseline)
Severe pre-eclampsia if one or more of the following:
 •    Sustained SBP $ 160 mmHg or DPB $ 110 mmHg  
(measured twice, at least six hours apart)
 •  evidence of other end-organ damage
     Deteriorating renal function including nephrotic range 
proteinuria $ 3 g/24 hours or 3+ on urine dipstick or  
sudden oliguria, especially with elevated creatinine†
   CNS disturbance (altered vision, headache)
   Pulmonary edema (3% of patients)
   Liver dysfunction
   epigastric/right upper quadrant pain (stretching of hepatic capsule)
   Thrombocytopenia (15%–30% of patients)
   HeLLP (may occur without proteinuria)
     evidence of fetal compromise (IUGR, oligohydramnios, 
nonreassuring fetal testing)
Notes: *Onset of pre-eclampsia at $ 34 weeks’ gestation is associated with a less 
severe form of the disease while onset before that time is associated with more 
severe disease and greater maternal and fetal morbidity;5 †Proteinuria or oliguria 
without an elevation in creatinine or other ominous signs may not indicate a serious 
worsening of severity of the disease.7
Abbreviations: IUGR, intrauterine growth retardation; HeLLP, hemolysis, elevated 
live enzymes, and low platelet count; CNS, central nervous system; SBP, systolic 
blood pressure; DBP, diastolic blood pressure.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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This   randomly collected, quantitative spot test correlates 
with 24-hour urinary protein study in a variety of patient 
  populations, while urine dipstick tests are qualitative tests 
that are poor predictors of total protein levels.8 Because of the 
importance of quickly and positively identifying those women 
with significant proteinuria, much research has been directed 
at determining what an appropriate cutoff for UPCR should 
be to provide the most sensitive results. If pre-  eclamptic 
ranges of proteinuria could be ruled out, the number of 
women who require hospital admission for testing, or who 
are required to perform an at-home 24-hour urine collection 
unnecessarily, could be reduced. In this regard, the UPCR 
could be a cost-effective, time-saving tool in diagnosing or 
more accurately ruling out the diagnosis of pre-eclampsia. 
Unfortunately, identifying a reliable cutoff value for a criti-
cal level is problematic, and the inadequacies of many of the 
studies to address the problem are significant.7,9
Lindheimer and Kanter provide a detailed discussion of 
proteinuria in pregnancy and a thoughtful critique of a num-
ber of studies on UPCR. The shortcomings of using UPCR 
to diagnose pre-eclampsia include inadequate evaluation of 
protein excretion in 24-hour urine collections used for com-
parison, common use of correlation coefficients rather than 
Bland-Altman plots, and, perhaps even more compelling, the 
fact that urine levels vary throughout the day and from day 
to day.7 While UPCR might provide a useful point-in-time 
estimate of proteinuria in the future, if the correct assessment 
study tools are utilized, the 24-hour urine study remains the 
gold standard for diagnosing pre-eclampsia.
HELLP syndrome is a related disorder of pregnancy 
characterized by hemolysis, elevated liver enzymes (liver 
dysfunction), and low platelet count (thrombocytopenia). 
HELLP may or may not occur in conjunction with proteinuria 
or hypertension, although the majority of patients will also 
have pre-eclamptic symptoms.4,10 HELLP is considered to 
be a severe form of disease, so its management may include 
prompt delivery of the fetus whether or not proteinuria or 
hypertension is present.
Eclampsia is the new onset of grand mal seizures occurring 
during or after pregnancy that do not have another identifiable 
cause. Unfortunately, it can occur with or without other prior 
symptoms, such as hypertension and proteinuria. Central ner-
vous system involvement in pre-eclampsia resulting in   seizures 
is also likely to be multifactorial, and may include cerebral 
vasoconstriction, ischemia, edema, or other pathologies. 
Although it is more likely to occur in women with severe than 
mild pre-eclampsia, there are no reliable tests or symptoms 
for predicting when eclampsia might develop. The overall risk 
of seizure is approximately 1% and can occur at virtually any 
time, ie, antepartum (38%–53%), intrapartum (18%–36%), and 
postpartum (11%–44%).11 Magnesium s  ulfate has been proven 
in large, multicenter and/or multinational trials to reduce the 
risk of seizure in severe pre-eclampsia and is commonly pre-
scribed for these patients.1,11
Screening for high-risk parturients
Risk factors for the development of pre-eclampsia are 
  numerous (see Table 2), and early identification of those 
women at highest risk has been the subject of much research 
in the past decade, including research into biochemical 
  markers associated with the disease, development of   Doppler 
  ultrasound tools for evaluating early uterine blood flow 
  patterns, and assessment of significant patient characteristics. 
Biochemical and ultrasound tests are founded on the various 
hypotheses about the etiology of pre-eclampsia, including 
abnormal or inadequate invasion of trophoblastic cells into 
the spiral arteries, the inflammatory and immune responses 
of first pregnancies, and genetic components. Ideally, early 
identification of high-risk parturients would lead to timely 
interventions to prevent the onset of pre-eclampsia or to 
minimize the risks of complications.
When considering potential screening tests for pre-
eclampsia, the relative importance of false positive and false 
negative findings are salient. Cnossen et al provide a useful 
and illustrative example of these concepts, and show how the 
magnitude of diagnostic error varies depending on the sensi-
tivity and specificity of a test and the estimated prevalence of 
the disease.12 While the results of a false positive prediction 
may be of some cost in terms of increased surveillance and 
testing, it is likely to be of minimal harm. For example, the 
use of low-dose aspirin is likely to have few detrimental 
effects. On the contrary, a false negative prediction may 
prevent appropriate treatment, thereby increasing the risk of 
Table 2 Risk factors for pre-eclampsia
•   Maternal obstetric factors: nulliparity, history of pre-eclampsia, 
multiple gestation pregnancy, gestational hypertension, molar 
pregnancy3
•   Maternal comorbid conditions: chronic hypertension, pregestational 
vascular/endothelial/renal disease, pregestational diabetes
•   Maternal genetic factors: antiphospholipid antibody, Factor v Leiden 
mutation (protein C resistance), first-degree relative  
with a pre-eclamptic pregnancy32
• Maternal lifestyle factors: obesity, smoking
• Other maternal factors: African-American race, age .40 years
•   Paternal obstetric factors: paternity by male who fathered a previous 
pre-eclamptic pregnancy in another woman, paternity by a male born 
from a pre-eclamptic pregnancy32International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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developing pre-eclampsia and resulting in increased mater-
nal and neonatal complications. In this regard, tests that are 
more highly sensitive are preferable for the identification 
of women at risk for pre-eclampsia. Unfortunately, in their 
meta-analysis of 219 studies, only uterine artery Doppler 
measurements reached measurements with greater than 60% 
sensitivity.
A widely accepted and verified method of early detec-
tion of pre-eclampsia continues to defy investigators and 
practitioners. As recently as 2004, Conde-Agudelo et al on 
behalf of the World Health Organization failed to identify 
any useful screening tests in a statistical review of all cohort 
or cross-sectional studies reporting data on the relationship 
between predictive tests and development of pre-eclampsia.13 
Perhaps the most promising current avenue of research for 
early detection is that using combinations of biochemical 
markers and Doppler ultrasound.
Giguère et al recently published a statistical review of 
the existing literature on markers of pre-eclampsia used to 
identify women at risk for pre-eclampsia. They found that 
the combination of both biochemical and biophysical (eg, 
Doppler ultrasound) markers improved the predictability of 
pre-eclampsia in both low- and high-risk women.14 Unfor-
tunately, the analysis of studies provided by Giguère et al is 
limited by the heterogeneous nature of the underlying studies, 
including the fundamental problem of defining precisely what 
constitutes pre-eclampsia in a low- or high-risk population 
across different countries.
Uterine artery Doppler measurement may be useful 
in predicting complications of early-onset pre-eclampsia 
(,34 weeks’ gestation).6 As noted above, early-onset 
pre-eclampsia is associated with defective trophoblastic 
invasion and subsequent placental insufficiency and growth 
  restriction.15 Abnormal uterine artery Doppler results at the 
time of admission in women with severe pre-eclampsia have 
been significantly correlated with an increased risk of mater-
nal and fetal complications, including HELLP, acute renal 
failure, pulmonary edema, maternal neurologic symptoms 
and lower birthweight, increased likelihood of small for 
gestational age at delivery, increased risk of acidosis, and 
a five-minute Apgar score of ,7 for the neonate.15 Uterine 
artery Doppler assessment could lead to increased antepartum 
surveillance and assist in planning for postpartum care of both 
the mother and neonate when results are abnormal.
While there are still no widely accepted biochemical mark-
ers for early detection of pre-eclampsia, there are numerous 
maternal and pregnancy characteristics that have long been 
identified as risk factors for pre-eclampsia (Table 2).3,16 Many 
of the risk factors are related to vascular disease, including a 
history of hypertension, chronic renal disease, and diabetes. It 
is becoming clear that pre-eclampsia is itself   associated with 
later development of cardiovascular disease. In a secondary 
review that was part of a larger study evaluating aspirin use 
as preventative medication, 25% of 763 women with chronic 
hypertension developed pre-  eclampsia.3 Bellamy et al 
  performed a meta-analysis of studies to investigate the link 
between pre-eclampsia and cardiovascular disease and can-
cer. They found that women with early onset of pre-  eclampsia 
(defined as ,37 weeks’   gestation) were more likely to have 
recurrence of pre-eclampsia in later pregnancies and were 
seven times more likely to subsequently develop hyperten-
sion. The commonality between risks for cardiovascular 
disease and pre-eclampsia supports the theory of a common 
causal link between the diseases, such as with angiogenic 
peptides and their inhibitors, which have been found to play 
a role in both disease states.17
Prevention
Given the significant morbidity and mortality associated 
with pre-eclampsia, especially with early onset, obstetric 
management has also been directed at disease prevention. 
Prophylactic use of aspirin and calcium has been studied for 
this effect with mixed results. More recently, appreciation 
of the role of obesity as a risk factor for pre-eclampsia has 
prompted interest in measuring the impact of bariatric surgery 
to decrease this risk.
Aspirin
An imbalance between thromboxane and prostacyclin levels 
is thought to be a significant factor in the development of 
pre-eclampsia. Taken in low doses, aspirin has been shown 
to decrease platelet production of thromboxane relative to 
prostacyclin.18 The PARIS (Perinatal Antiplatelet Review 
of International Studies) Collaboration meta-analysis of 
32,217 women in 38 trials found that aspirin use was associ-
ated with a 10% relative reduction in the risk of developing 
pre-eclampsia, as well as birth before 34 weeks, but did not 
impact fetal mortality.19 However, they were also unable to 
identify any particular subgroup that would benefit more 
from taking aspirin. In a more recently published meta-
analysis, women at high risk for developing pre-eclampsia, 
as identified by abnormal uterine artery Doppler, who were 
given aspirin before 16 weeks’ gestation, were found to have 
a greater than 50% relative risk reduction, while those who 
began taking aspirin at 17–19 and $20 weeks’ gestation had 
45% and 18% reductions, respectively.20 It remains unclear International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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if aspirin should be recommended in patients who are not 
at high risk for developing pre-eclampsia, even though it 
is recognized to be a low-risk intervention, when started 
after the first trimester. The American College of Obstetrics 
and Gynecology (ACOG) recommendations have not been 
changed recently and do not currently include the use of 
aspirin to prevent pre-eclampsia.4
Calcium
Calcium supplementation has been associated with a 
reduction in hypertension and with reduced occurrence of 
pre-eclampsia in populations with a low baseline of dietary 
calcium intake. Hofmey et al performed a systematic review 
of 12 randomized trials including a total of 15,528 women 
as reported in the Cochrane Pregnancy and Childbirth 
Group Trials Register and the Cochrane Central Register of 
Controlled Trials. Based on this review they concluded that 
calcium supplementation reduced the risk of pre-eclampsia, 
noting that most women in the study were low-risk but also 
had low dietary intake of calcium.21 Kumar et al recently pub-
lished results of a randomized, placebo-controlled study of 
584 primigravid women taking lower than the recommended 
dietary calcium of 1 g/day. In this study, the incidence of pre-
eclampsia was significantly less in the calcium supplement 
2 g/day group than in the placebo group (odds ratio 0.51 
with a 95% confidence interval).22 Calcium supplementation 
also appeared to reduce the risk of preterm delivery in the 
treatment group.
Unfortunately, while calcium supplementation may be 
associated with decreased occurrence of pre-eclampsia in 
patients with low dietary intake, its benefit to women with 
baseline intake at or above the recommended level has not 
been proven. Thus, while calcium supplementation is unlikely 
to be harmful, it is also unlikely to be helpful in preventing 
pre-eclampsia in women with a normal diet in developed 
countries. The ACOG practice bulletin does not recommend 
the use of calcium to prevent pre-eclampsia.3
Bariatric surgery
Obesity is recognized as a contributing factor in a wide 
range of diseases but its importance as a modifiable risk fac-
tor for pre-eclampsia may have been overlooked. Bariatric 
surgery is proven to mitigate the pathophysiologic effects 
of obesity on the cardiovascular and endocrine systems.23,24 
The relationship between obesity and pregnancy-related com-
plications is a complex one, involving the increased inflam-
matory state associated with obesity and the increased risk 
of other comorbidities, such as diabetes, hypertension, and 
pre-eclampsia. Thus, the effects of obesity alone on outcomes 
such as prematurity are difficult to measure separately.25 Just 
as bariatric surgery is a proven way to improve overall health 
in obese patients, there is also evidence that it decreases the 
rates of pre-eclampsia and eclampsia in some obese women 
of childbearing age. Bennett et al performed a retrospective 
cohort study on insurance claims data of 585 women aged 
16–45 years, and found that those who had bariatric surgery, 
most commonly gastric bypass, prior to delivery had a 75% 
lower risk of developing a hypertensive disorder in pregnancy 
compared with those who delivered after surgery. These results 
further support the use of bariatric surgery in women with 
BMI . 40 (Class III obesity) and those with BMI $ 35 plus 
other significant comorbidities, such as diabetes and hyper-
tension, and may prove an important intervention to prevent 
pre-eclampsia in high-risk patients.26 It is unclear if weight 
loss alone, independent of bariatric surgery, would provide 
a similar benefit.
Pathogenesis and pathophysiology
Pre-eclampsia is a complex, multisystem disease and numer-
ous models have attempted to explain its pathogenesis. An 
abnormal invasion of trophoblastic tissue into the maternal 
uterine wall at about 12–13 weeks’ gestation is thought to 
result in early-onset pre-eclampsia, as described above. In 
pre-eclampsia, the extravillous trophoblastic cells fail to 
invade beyond the decidual to the myometrial layers, so that 
spiral artery blood flow remains in a state of high resistance 
and low flow, with resulting hypoperfusion and hypoxemia 
of the placenta.27,28
Investigation of the cellular mechanisms and pathology 
that occur in remodeling of the spiral arteries has led to a 
better understanding of the important role of immunology 
in pre-eclampsia. Cytokines and growth factors, including 
tumor necrosis factor, are produced by trophoblastic cells 
and are an important area of research on the etiology of 
pre-eclampsia. Impairment of the normal maternal immune 
response, possibly mediated by lower than normal oxygen 
tension and underexpression of angiogenic factors, may 
partly explain why abnormal trophoblastic invasion occurs 
in some pregnancies.29,30 Placental hypoxia causes release of 
cytokines and inflammatory factors that result in maternal 
endothelial damage.28,30
Endothelial damage is the crux of the multitude of 
pathophysiologic effects of pre-eclampsia (HELLP, cere-
brovascular disease, hypertension) and causes an imbalance 
between thromboxane and prostacyclin, resulting in com-
promised uteroplacental circulation.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Platelet dysfunction has been implicated in pre-  eclampsia, 
with surface-mediated platelet activation, decreased 
  sensitivity to prostacyclin, and increased release of throm-
boxane and serotonin, leading to further platelet aggregation 
and upregulation of the uteroplacental renin angiotensin 
aldosterone system.20,31
Genetics have also been implicated in the pathogenesis of 
pre-eclampsia. Women with a first-degree relative who had 
pre-eclampsia are more likely to develop the disease. Interest-
ingly, men who were born from a pre-eclamptic pregnancy 
are more likely to be fathers in a pre-eclamptic pregnancy.32 
These familial patterns have also been associated with more 
severe disease.
As the variety of models of pre-eclampsia suggest, the 
pathophysiology is complex and involves virtually every 
organ system. Some of the most common signs and symptoms 
are presented in Table 3.31,33
Obstetric management
Obstetric management of pre-eclampsia relies on a high index 
of suspicion, careful observation, and early intervention.4 The 
method of intervention is logically a function of the severity 
of the disease, but ultimately the only definitive treatment is 
delivery of the fetus and placenta.
Mild pre-eclampsia
The treatment of mild pre-eclampsia is supportive until 
delivery and may include complete or partial bed rest with 
frequent fetal monitoring as part of expectant   management. 
Sibai recommends conservative management of mild 
  pre-eclampsia, since perinatal outcomes are similar to those 
in normotensive pregnancies.34
The ACOG practice bulletin on hypertensive disorders 
unique to pregnancy suggests monitoring according to 
the recommendations of the National High Blood Pres-
sure   Education Program Working Group. These are fetal 
  monitoring with daily fetal movement counts, weekly 
nonstress tests or biophysical profiles, or both, ultrasound 
examination for fetal growth and amniotic fluid assessment 
every 3–4 weeks, maternal tests including BP and laboratory 
tests to check hematocrit and platelet count, liver enzymes, 
renal function, and 12- or 24-hour urine protein collections at 
least weekly.4 Doppler flow velocimetry may also be used to 
assess for fetal status. The goal of monitoring these women 
is to identify patients with evidence of increasing disease 
severity. Progression of the disease warrants hospitalization 
for closer observation and medical management.
The rate of eclamptic seizures in women with mild pre-
eclampsia is less than 1%. Use of magnesium sulfate to 
  prevent eclamptic seizures in women with mild pre-eclampsia 
is controversial, and the ACOG practice bulletin stops short 
of recommending it in this case.34,4 A statistical decision 
analysis comparing the use versus nonuse of magnesium 
sulfate in women with mild pre-eclampsia found that nonuse 
reduced fetal mortality by 15% and avoided maternal toxicity, 
while maternal mortality was increased two-fold and fetal 
neurologic complications increased with use of magnesium. 
The two treatments were both deemed acceptable and treat-
ment decisions should be based on individual physician and 
patient judgements.35
Induction of labor (IOL) for women at 37 weeks’ ges-
tational age with a favorable cervix and for noncompliant 
women is recommended, and prostaglandin therapy should 
be considered for cervical ripening in those women with 
an unfavorable cervix at or near term.34,5 In the HYPITAT 
(Hypertension and Pre-eclampsia Intervention Trial at Term), 
a multicenter, randomized controlled study comparing IOL 
versus expectant monitoring in women with mild hyper-
tensive disease, IOL was shown to improve a composite of 
maternal outcomes including eclampsia, HELLP, pulmonary 
edema, placental abruption, and major hemorrhage in women 
beyond 37 weeks’ gestation, with no significant difference in 
neonatal outcomes and a lower rate of cesarean delivery.36
Severe pre-eclampsia
In cases of severe pre-eclampsia, the main goals of therapy 
are to control BP and to prevent eclampsia, with vaginal 
Table  3  Pathophysiology:  Potential  signs  and  symptoms  of 
pre-eclampsia31,33
•   Central nervous system: headaches, visual changes, hyperexcitability, 
hyperreflexia, and seizures (eclampsia)
•   Cardiovascular system: increased sensitivity to endogenous controls 
(hormonal/autacoid); an early hyperdynamic state may change to a low-
output, high total vascular resistance; intravascular volume depletion33
•   Respiratory system: pharyngolaryngeal edema; increased risk of 
pulmonary edema due to lower colloid oncotic pressure and increased 
vascular permeability
•   Hematologic system: hypercoagulability, platelet activation with 
microvascular consumption; activation of fibrinolytic system
•   Renal system: decreased glomerular filtration rate; increased 
proteinuria; increased uric acid; increased urine protein:creatinine 
ratio; oliguria
•   Hepatic system: increased serum transaminases; hepatic edema/right 
upper quadrant abdominal pain; rupture of Glisson’s capsule with 
hepatic hemorrhage
•   endocrine system: imbalance of prostacyclin relative to thromboxane; 
upregulation of systemic renin angiotensin aldosterone system31
•   Uteroplacental system: persistence of a high-resistance circuit with 
decreased blood flow; intrauterine growth restriction; oligohydramnios.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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delivery for appropriate patients and cesarean section in cases 
of urgency or when induction of labor fails, with timing bal-
anced by the safety of the mother against the risk of delivery 
of a potentially premature fetus. Expectant management is 
reserved only for select patients who are far from term but 
who are stable on antihypertensive medications, with stable 
laboratory values and a reassuring fetal biophysical profile. 
Expectant management should include criteria for delivery 
and only occur at a tertiary care hospital with close maternal 
and fetal monitoring.4,10,34,37
Medications commonly used by obstetricians to treat 
hypertension associated with severe pre-eclampsia include 
hydralazine, labetalol, and nifedipine (or other calcium chan-
nel blockers) with a goal diastolic BP of 90–105 mmHg and 
systolic BP of 140–155 mmHg or a mean arterial pressure 
of 105–125 mmHg. Hydralazine may be associated with 
increased maternal side effects and may be more poorly 
tolerated than labetalol and nifedipine, both of which are 
reasonable alternatives.38 Nitroglycerin or nitroprusside are 
used to manage hypertensive emergencies, eg, hypertensive 
encephalopathy.31
Seizure prophylaxis is routinely accomplished with 
magnesium sulfate using a 4–6 g intravenous loading dose, 
then a 1–2 g/hour infusion, with a goal serum concentration 
of 5–8 mg/dL. In patients for whom BP is successfully sta-
bilized, magnesium sulfate may be discontinued with close 
monitoring on a high-risk antepartum ward until the time of 
delivery, at which time it is restarted. Due to the continued 
risk of eclampsia, the infusion continues for at least 24 hours 
postpartum.39 Of note, nifedipine has been safely used in con-
junction with magnesium sulfate without significant evidence 
of increased serious magnesium-related side effects, such as 
muscle weakness.38
Since definitive treatment of pre-eclampsia is delivery of 
the fetus and placenta, preferably vaginally, IOL may be war-
ranted. IOL is considered in cases of $37 weeks’ gestational 
age, fetal lung maturity (32–34 weeks’ gestational age),40 a 
favorable cervix, and maternal or fetal deterioration despite 
conservative management. Corticosteroids to accelerate fetal 
lung maturity should be considered in those with gestational 
ages of 24–34 weeks, and delivery should commence 48 hours 
later in those with gestational ages of 33–34 weeks.34,37 Intra-
uterine growth restriction is a sign of chronic uteroplacental 
insufficiency, and may be another factor recommending 
prompt delivery after steroids have been administered, espe-
cially when combined with oligohydramnios.41 There are 
numerous maternal and fetal indications for urgent delivery 
relating to worsening of the disease state (Table 4).
Women with HELLP should be delivered regardless of 
gestational age, but if expectant management is planned, 
it should only occur at a tertiary care hospital with close 
maternal and fetal monitoring due to the severe nature of the 
disease.4 It seems reasonable to recommend prompt delivery 
within 48 hours of diagnosis of HELLP, allowing for corti-
costeroid therapy for lung maturation, because there is some 
evidence that prolongation of pregnancy may not improve 
neonatal outcomes.37
Anesthetic management
The anesthetic management of patients with pre-eclampsia 
plays an important role in the peripartum period. The 
anesthesiologist must perform a thorough preanesthetic 
evaluation, including a history and physical examination, 
with careful attention to the airway examination due to the 
increased risk of pharyngolaryngeal edema,42,43 and assess-
ment of the patient’s cardiopulmonary, fluid, and coagulation 
status. Fasting should be considered in very active high-risk 
patients to decrease the risk of aspiration should cesarean 
section become necessary. Laboratory values including 
urine protein, platelet counts, liver enzymes, and possibly a 
coagulation panel, should be obtained.
An appropriate understanding of the implications of 
obstetric interventions, including the use of magnesium 
sulfate, is important for the anesthetic management of pre-
eclampsia. Magnesium sulfate causes direct vasodilation that 
can improve uteroplacental blood flow and lower BP, and 
has some analgesic properties that are enhanced by volatile 
anesthetics. It also has many potentially deleterious effects, 
especially at toxic levels (Table 5).39,44
Anesthetic management of pre-eclamptic patients 
requires appropriate monitoring and should at a minimum 
include BP, pulsoximetry, and a Foley catheter. While not 
common, invasive monitoring is sometimes required. An 
arterial line may be indicated in the severely pre-eclamptic, 
Table 4 Urgent indications for delivery in pre-eclampsia10,37,41
• Severe, refractory hypertension .24 hours
• Refractory renal failure
• Pulmonary edema
•   Worsening thrombocytopenia, coagulopathy/disseminated 
intravascular coagulopathy
• Progressive liver dysfunction or hepatic hematoma/rupture
• eclampsia or progression of neurologic symptoms
• Placental rupture
•   evidence of severe fetal growth restriction or oligohydramnios  
(may consider delay for betamethasone therapy)41
• Fetal distressInternational Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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poorly controlled parturient or when noninvasive BP 
monitoring is difficult to obtain. Central venous pressure 
monitoring is indicated in patients with pulmonary edema, 
severe renal disease, and when difficult fluid management 
in the peripartum period is anticipated. A pulmonary artery 
catheter is rarely needed, but may be useful in the peripartum 
management in cases of severe cardiac/valvular disease, 
significant pulmonary hypertension, severe and refractory 
hypertension, and persistent oliguria.
Pulmonary edema is a rare, serious problem   complicating 
as many as 3% of cases of severe pre-eclampsia.45 An 
echocardiogram should be obtained if there is any concern 
of a cardiac etiology (eg, cardiomyopathy), time permitting. 
The risk of pulmonary edema increases with age and parity 
and often occurs postpartum in association with excess fluid 
administration or heart failure. In one study of pulmonary 
edema, maternal mortality was reported to be greater than 
10% and perinatal mortality greater than 50%.45
In cases of peripartum bleeding due to uterine atony, 
ergot alkaloids (eg, methergine) should be avoided in patients 
with elevated BP due to the risk of hypertensive crisis. 
  Methylprostaglandin F2α (hemabate) may be considered if 
oxytocin fails to achieve appropriate uterine contractility.
The ACOG and the American Society of Anesthesiolo-
gists (ASA) recommend that regional anesthesia be used 
in pre-eclamptic patients without coagulopathy in order to 
decrease the need for general anesthesia should an emergent 
procedure become necessary.4,46 General anesthesia may 
increase the risk of complications, such as cerebral hemor-
rhage due to BP changes associated with rapid sequence 
induction of anesthesia.47 In severe cases, the insertion of an 
epidural catheter may precede the onset of labor or a patient’s 
request for labor analgesia.46 While the ASA guidelines indi-
cate spinal catheters may be placed early in these high-risk 
patients, there is some evidence that these catheters are more 
likely to fail and have more complications, such as difficult 
removal, when compared with epidural catheters used for 
labor analgesia.48 Unfortunately, spinal catheters have not 
been studied for use in the pre-eclamptic patient population. 
Given the availability of fast-acting local anesthetics, such a 
3% chloroprocaine for epidural use, should urgent cesarean 
section become necessary, one could argue that epidural 
catheters have a better safety profile than spinal catheters in 
pre-eclamptic patients.
Regional anesthesia may decrease the swings in BP 
  exacerbated by the pain response in pre-eclampsia.49 
  Depending on the patient’s hemodynamic and volume 
status, judicious volume expansion may be considered prior 
to regional anesthesia, but caution should be used to avoid 
fluid overload given the increased risk of pulmonary edema. 
A number of studies in the last decade have demonstrated 
that spinal and combined spinal-epidural anesthesia can be 
safely administered without significantly increasing the risk 
to the mother and fetus, even in severe pre-eclampsia.50,51 In 
a randomized, controlled trial (n = 100), Visalyaputra et al 
showed that while there was a brief period of increased 
hypotension in severely pre-eclamptic patients receiving 
spinal versus epidural anesthesia, there were no clinical dif-
ferences in fetal or maternal outcomes.50 Aya et al found in 
a prospective cohort study (n = 60) that patients with severe 
pre-eclampsia had a decreased hemodynamic response to a 
combined spinal-epidural relative to healthy parturients after 
volume loading of all patients with 1500 cc of crystalloid.52 
Aya et al later concluded that pre-eclampsia-associated 
factors are more likely related to the decreased risk of 
hypotension rather than decreased aortocaval compression 
in a study comparing spinal anesthesia between otherwise 
healthy preterm patients and those with severe pre-eclampsia 
undergoing cesarean section.53
While regional anesthesia is associated with a decrease in 
maternal mortality, general endotracheal anesthesia (GETA) 
is still necessary in some cases. Indications for GETA 
include suspected placental abruption, coagulopathy,   platelet 
count less than 80,000–100,000/µL in the pre-eclamptic 
patient, severe pulmonary edema, eclampsia, and severe 
fetal distress. GETA in pre-eclampsia may increase the risk 
of hypertension, aspiration, loss of airway, and transient 
neonatal depression; the maternal mortality risk of GETA 
remains approximately seven-fold greater than for regional 
anesthesia.54 While absolute maternal mortality is low, one 
half of obstetric deaths with GETA are due to failed airway 
management.55 As noted above, severe pre-eclampsia may 
be associated with pharyngolaryngeal edema,42,43 increasing 
the risk of difficult intubation and, while failed intubation is 
rare, it is still 10 times more likely in obstetric patients, ie, 
1/280 obstetric cases versus 1/2230 in general operating room 
cases.54,55 These statistics emphasize the important role that 
Table 5 Side effects of magnesium sulfate
• Nausea, headache, flushing, weakness
• Decreased uterine tone
• Augmentation of neuromuscular blockade
• Mild analgesia44
•   Toxicity (therapeutic range 5–8 mg/dL) 
Loss of deep tendon reflexes at 9–12 mg/dL 
Respiratory depression at 15–20 mg/dL 
Cardiovascular collapse at .25 mg/dLInternational Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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regional anesthesia can play in the safe-keeping of women 
with pre-eclampsia.
Should GETA become necessary, careful management of 
BP, especially during laryngoscopy and intubation, should be 
used because severe hypertension may increase the risk of 
significant maternal morbidity and mortality, including cere-
bral hemorrhage, in pre-eclamptic patients. Care should be 
taken to ensure an adequate depth of anesthesia and   preparation 
for BP changes during intubation, even in the presence of fetal 
distress, because intracranial hemorrhage is a leading cause 
of death in these patients. This point is emphasized in the 
2007 publication “Saving Mothers’ Lives” by the Confidential 
Enquiry into Maternal and Child Health (now known as the 
“Centre for Maternal and Child Enquiries”).56 To decrease 
the response to laryngoscopy, short-acting opioids and anti-
hypertensives such as remifentanil, esmolol, and nitroglycerin 
may be useful, and continuation of magnesium infusion may 
be considered. Remifentanil has been shown to successfully 
attenuate heart rate, BP, and catecholamine responses to 
laryngoscopy and endotracheal intubation in both healthy57 
and severely pre-eclamptic patients58 undergoing GETA for 
cesarean delivery. Unfortunately, opioids do cross the placenta 
and increase the risk of neonatal respiratory depression, so 
use in cesarean delivery should be limited to clear indications, 
such as severe pre-eclampsia, and to use where facilities for 
neonatal resuscitation are available. Because remifentanil 
is rapidly metabolized in the blood stream, any respiratory 
depression observed should be brief, and five-minute Apgar 
scores in treatment and nontreatment groups have been 
similar.57,58 Of course, maternal hypotension upon induction 
of general anesthesia can also occur, with or without the use 
of remifentanil, and the anesthesiologist should be prepared 
to deal quickly with this problem as well.
Summary
Pre-eclampsia is a relatively frequent syndrome, occurring in 
5%–8% of pregnancies, and remains the third leading cause 
of maternal mortality in the US. The causes are multifactorial, 
and the disease is characterized by endovascular and platelet 
dysfunction with intense vasoconstriction, leaky capillar-
ies, and intravascular volume contraction culminating in 
multiorgan hypoperfusion, with the potential for significant 
end-organ damage, including eclamptic seizures. Efforts at 
early diagnosis have included use of protein/creatinine ratios 
and uterine artery Doppler flow studies. Research to iden-
tify biochemical markers early in pregnancy continues, but 
screening tools remain insufficient for reliable, widespread 
implementation.
Prevention of pre-eclampsia is an ongoing challenge. 
Aspirin may decrease the risk of developing pre-eclampsia 
in certain high-risk women if started early enough in the 
pregnancy. Calcium supplementation may decrease the 
risk of developing pre-eclampsia in populations with lower 
than the recommended daily calcium intake. Neither aspirin 
nor calcium has been proven sufficiently beneficial to be 
  recommended for use in prevention of pre-eclampsia by the 
ACOG. Interestingly, bariatric surgery has been shown to 
decrease the risk of pre-eclampsia by 75% in significantly 
obese women and in those who are mildly obese with related 
comorbidities, such as diabetes and hypertension.
Obstetric management of severe cases includes BP control 
and seizure prophylaxis with magnesium sulfate. Expectant 
management is appropriate for mild cases and in severe cases 
with close monitoring of the mother and fetus and timely 
delivery balancing neonatal development with maternal risk. 
In severe cases of maternal disease or fetal compromise, deliv-
ery is generally recommended after 34–37 weeks’ gestation or 
earlier, possibly after administration of corticosteroids.
Early careful assessment by an anesthesia provider is 
recommended for all patients with pre-eclampsia, especially 
in severe cases. Unless there is a known contraindication, 
such as coagulopathy, regional anesthesia is recommended 
for pre-eclamptic patients. ASA guidelines recommend that 
early placement should be considered in severe cases, in part 
to avoid the risks of general anesthesia, given the increased 
risk of urgent operative delivery. Given the risks of GETA 
in the pre-eclamptic parturient, spinal anesthesia should be 
considered in cases of urgency without indwelling epidural.59 
When GETA is required, it is crucial to anticipate and treat 
BP lability. It is also imperative to be prepared for manage-
ment of the difficult parturient airway, given the increased 
risk of pharyngolaryngeal edema.
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